表紙
市場調查報告書

藥物輸送:經皮吸收貼片

Drug Delivery: Transdermal Devices

出版商 Datamonitor Healthcare 商品編碼 939977
出版日期 內容資訊 英文 76 Pages
商品交期: 最快1-2個工作天內
價格
藥物輸送:經皮吸收貼片 Drug Delivery: Transdermal Devices
出版日期: 2020年04月15日內容資訊: 英文 76 Pages
簡介

全球經皮吸收貼片市場預測將從2019年的49億美元擴大到2024年55億美元的規模,年複合成長率預測將為2.4%。

本報告提供全球經皮吸收貼片市場調查,提供技術概要,對應可能的疾病,各種市場分析等資訊。

目錄

摘要整理

  • 經皮吸收貼片產品市場概要
    • 市場成長要素及阻礙因素
    • 心血管疾病
    • 神經病變
    • 荷爾蒙補充療法
    • 疼痛管理
    • 市場領導者
    • 新興企業
  • 調查手法
  • 參考文獻

第1章 經皮藥物輸送技術

  • 技術
    • 被動式
    • 主動式
  • 臨床應用
  • 參考文獻

第2章 經皮藥物遞輸系統

  • 心血管疾病的管理
    • 心絞痛
    • 高血壓
    • 產品
    • 新產品
  • 神經病變管理
    • 注意力不足過動症(簡稱過動症)
    • 阿茲海默症
    • 重度憂鬱症
    • 帕金森氏症
    • 產品
    • 新產品
  • 荷爾蒙補充療法
    • 閉經
    • 骨質疏鬆症
    • 產品
    • 新產品
  • 疼痛管理
    • WHO方式疼痛梯度
    • 產品
  • 參考文獻

第3章 經皮藥物遞輸系統的市場

  • 心血管疾病的管理
    • 市場分析
    • 競爭分析
  • 神經病變管理
    • 市場分析
    • 競爭分析
  • 荷爾蒙補充療法
    • 市場分析
    • 競爭分析
  • 疼痛管理
    • 市場分析
    • 競爭分析

附錄:相關企業的清單

目錄
Product Code: #MDT20004

Overview

In 2019, global sales of transdermal patch products targeting the conditions covered by this analysis totaled nearly $4.9bn, and is expected to increase at a CAGR of 2.4% over the forecast period, reaching $5.5bn in 2024.*The neurological disorder patches segment is expected to grow at the fastest rate, with a 3.7% CAGR over the forecast period as a result of the large market size and large potentially targetable patient caseload, while the pain management patches market is expected to experience the most dollar sales growth through 2024. Market drivers include the increasing prevalence of CVD and other associated disorders as the population ages, and improved patient compliance with patch-based pharmacology compared to oral medication. Limiters include declines in mature market segments, and strong competition from oral pharmaceuticals and generic equivalents.

This report provides:

  • an overview of transdermal drug delivery technology, including active and passive transport systems
  • key epidemiology data on the prevalence of*angina pectoris, hypertension, Alzheimer's disease, ADHD, major depressive disorder, Parkinson's disease, menopause, osteoporosis, cancer-related pain, and post-herpetic neuralgia in major world regions
  • related product portfolios offered by leading manufacturers
  • top selling transdermal drug delivery devices, as well as emerging products under development
  • in-depth market and competitive analyses for 2019-24 for the US, five major European markets, Japan, and RoW markets.

Table of Contents

Executive Summary

  • i. Transdermal drug delivery devices market
    • a. Selected market drivers and limiters
    • b. Cardiovascular disease patches segment
    • c. Neurological disorder patches segment
    • d. Hormone replacement therapy patches segment
    • e. Pain management patches segment
    • f. Market leaders
    • g. Emerging competition
  • ii. Methodology
  • iii. Bibliography
  • Exhibit ES-1: Transdermal drug delivery devices, combined market forecast ($m), by application, 2019-24
  • Exhibit ES-2: Transdermal drug delivery devices, combined market forecast, by region ($m), 2019-24

1. Transdermal Drug Delivery Technology

  • 1.1. Technology
    • 1.1.1. Passive transdermal transport systems
    • 1.1.2. Active transdermal transport systems
  • 1.2. Clinical applications
  • 1.3. Bibliography

2. Transdermal Drug Delivery Systems

  • 2.1. Cardiovascular disease management
    • 2.1.1. Angina pectoris
    • 2.1.2. Hypertension
    • 2.1.3. Products
    • 2.1.4. Emerging products
  • 2.2. Neurological disorder management
    • 2.2.1. Attention deficit hyperactivity disorder
    • 2.2.2. Alzheimer's disease
    • 2.2.3. Major depressive disorder
    • 2.2.4. Parkinson's disease
    • 2.2.5. Products
    • 2.2.6. Emerging products
  • 2.3. Hormone replacement therapy
    • 2.3.1. Menopause
    • 2.3.2. Osteoporosis
    • 2.3.3. Products
    • 2.3.4. Emerging products
  • 2.4. Pain management
    • 2.4.1. WHO analgesic ladder
    • 2.4.2. Products
  • 2.6. Bibliography
  • Exhibit 2-1: Age-standardized incidence of angina pectoris per 100,000 population, by region, 1990 and 2010
  • Exhibit 2-2: Estimated prevalence of systemic hypertension, by region, 2019
  • Exhibit 2-3: Mortality attributable to hypertensive diseases, by region, 2014
  • Exhibit 2-4: Selected patch-based clonidine and nitroglycerin products, 2020
  • Exhibit 2-5: Estimated prevalence of selected neurological conditions, by region
  • Exhibit 2-6: Selected patch-based neurological disorder therapies, 2020
  • Exhibit 2-7: Estimated prevalence of osteoporosis, selected countries, 2019
  • Exhibit 2-8: Selected patch-based hormone replacement therapies, 2020
  • Exhibit 2-9: Estimated prevalence of pain, selected countries, 2019
  • Exhibit 2-10: WHO analgesic ladder
  • Exhibit 2-11: Selected patch-based pain management therapies, 2020

3. Transdermal Drug Delivery Systems Market

  • 3.1. Cardiovascular disease management
    • 3.1.1. Market analysis
    • 3.1.2. Competitive analysis
  • 3.2. Neurological disorder management
    • 3.2.1. Market analysis
    • 3.2.2. Competitive analysis
  • 3.3. Hormone replacement therapy
    • 3.3.1. Market analysis
    • 3.3.2. Competitive analysis
  • 3.4. Pain management
    • 3.4.1. Market analysis
    • 3.4.2. Competitive analysis
  • 3.5. Bibliography
  • Exhibit 3-1: Patch-based pharmaceutical products, by application, combined market forecast ($m), 2019-24
  • Exhibit 3-2: Patch-based cardiovascular disease therapy products, market forecast, by country/region ($m), 2019-24
  • Exhibit 3-3: Boehringer Ingelheim, revenues by segment, 2019
  • Exhibit 3-4: Mylan Technologies, revenues by segment, 2019
  • Exhibit 3-5: Mayne Pharma, revenues by segment, 2019
  • Exhibit 3-6: Patch-based cardiovascular disease therapy products market, share by supplier, 2019
  • Exhibit 3-7: Patch-based neurological disorder therapy products, market forecast, by country/region ($m), 2019-24
  • Exhibit 3-8: UCB Group, revenues by segment, 2019
  • Exhibit 3-9: Novartis, revenues by segment, 2019
  • Exhibit 3-10: Hisamitsu Pharmaceutical, revenues by segment, 2019
  • Exhibit 3-11: Patch-based neurological disorder therapy products market, share by supplier, 2019
  • Exhibit 3-12: Patch-based hormone replacement therapy products, market forecast, by country/region ($m), 2019-24
  • Exhibit 3-13: Bayer, revenues by segment, 2019
  • Exhibit 3-14: Hisamitsu Pharmaceutical, HRT product sales, 2019
  • Exhibit 3-15: Patch-based hormone replacement therapy products market, share by supplier, 2019
  • Exhibit 3-16: Patch-based pain management products, market forecast, by country/region ($m) 2019-24
  • Exhibit 3-17: Endo Pharmaceuticals, revenues by segment, 2019
  • Exhibit 3-18: Patch-based pain management products market, share by supplier, 2019

Appendix: Company Listing